Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1998 1
2000 1
2002 1
2005 2
2006 1
2009 3
2012 3
2013 4
2014 3
2015 10
2016 5
2017 6
2018 6
2019 8
2020 11
2021 7
2022 9
2023 7
2024 8
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Graves' disease: Epidemiology, genetic and environmental risk factors and viruses.
Antonelli A, Ferrari SM, Ragusa F, Elia G, Paparo SR, Ruffilli I, Patrizio A, Giusti C, Gonnella D, Cristaudo A, Foddis R, Shoenfeld Y, Fallahi P. Antonelli A, et al. Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101387. doi: 10.1016/j.beem.2020.101387. Epub 2020 Feb 4. Best Pract Res Clin Endocrinol Metab. 2020. PMID: 32107168 Review.
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. WHO Solidarity Trial Consortium, et al. N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2. N Engl J Med. 2021. PMID: 33264556 Free PMC article. Clinical Trial.
Novel therapies for thyroid autoimmune diseases: An update.
Ferrari SM, Fallahi P, Elia G, Ragusa F, Camastra S, Paparo SR, Giusti C, Gonnella D, Ruffilli I, Shoenfeld Y, Antonelli A. Ferrari SM, et al. Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101366. doi: 10.1016/j.beem.2019.101366. Epub 2019 Nov 28. Best Pract Res Clin Endocrinol Metab. 2020. PMID: 31813786 Review.
An Investigation into Cell-Free DNA in Different Common Cancers.
Nafar S, Hosseini K, Shokrgozar N, Farahmandi AY, Alamdari-Palangi V, Saber Sichani A, Fallahi J. Nafar S, et al. Mol Biotechnol. 2024 Dec;66(12):3462-3474. doi: 10.1007/s12033-023-00976-9. Epub 2023 Dec 10. Mol Biotechnol. 2024. PMID: 38071680 Review.
Genomic testing identifies monogenic causes in patients with very early-onset inflammatory bowel disease: a multicenter survey in an Iranian cohort.
Eslamian G, Jamee M, Momen T, Rohani P, Ebrahimi S, Mesdaghi M, Ghadimi S, Mansouri M, Mahdaviani SA, Sadeghi-Shabestari M, Fallahpour M, Shamsian BS, Eslami N, Sharafian S, Dara N, Nasri P, Amini N, Enayat J, Fallahi M, Ghasemi Hashtrodi L, Shojaei M, Guevara Becerra M, Uhlig HH, Chavoshzadeh Z. Eslamian G, et al. Clin Exp Immunol. 2024 Jun 20;217(1):1-11. doi: 10.1093/cei/uxae037. Clin Exp Immunol. 2024. PMID: 38651248 Free PMC article.
Terahertz-driven linear electron acceleration.
Nanni EA, Huang WR, Hong KH, Ravi K, Fallahi A, Moriena G, Miller RJ, Kärtner FX. Nanni EA, et al. Nat Commun. 2015 Oct 6;6:8486. doi: 10.1038/ncomms9486. Nat Commun. 2015. PMID: 26439410 Free PMC article.
Conventional high-brightness radio-frequency accelerating structures operate with 30-50 MeV m(-1) gradients. Electron accelerators driven with optical or infrared sources have demonstrated accelerating gradients orders of magnitude above that achievable with conventional r …
Conventional high-brightness radio-frequency accelerating structures operate with 30-50 MeV m(-1) gradients. Electron accelerators dr …
89 results